



SHUKRA

PHARMACEUTICALS LTD.

16th July, 2024

To,
The Dy. Gen Manager
Corporate Relationship Dept.
BSE Limited
P. J. Tower, Dalal Street,
Mumbai- 400 001

Scrip Code: 524632

Dear Sir,

Sub: Reconciliation of share capital audit report as per Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018

Please find enclosed the Reconciliation of share capital audit report as per Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June30, 2024.

This is for your information and records.

Thanking you,

Yours sincerely,

For, SHUKRA PHARMACEUTICALS LIMITED


Bhoomi Patel
Director
DIN: 08316898



CIN : L24231GJ1993PLC019079

RECONCILIATION OF SHARE CAPITAL AUDIT

1. For Quarter ended on : **30th June, 2024**
2. ISIN : **INE551C01028**
3. Face Value : **Rs. 10/-**
4. Name of the Company : **SHUKRA PHARMACEUTICALS LIMITED**
5. Registered Office : **3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road,
Address Bodakdev, Ahmedabad, Gujarat, India, 380003**
6. Correspondence : **3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road,
Address Bodakdev, Ahmedabad, Gujarat, India, 380003**
7. Telephone & Fax No.: **Tel : 079 - 48000430**
8. E - mail Address: **info@shukrapharmaceuticals.com**
9. Names of the stock exchanges where the company's shares are listed **BSE Limited**
- | | No. of sha. | % of Cap. |
|---|-----------------------------|---------------|
| 10. Issued Capital : | 43787944 | 100 |
| 11. Listed Capital :
(Exchange - wise) | BSE Limited 43787944 | 100.00 |
| 12. Held in dematerialised form in CDSL : | 32469632 | 74.15 |
| 13. Held in dematerialised form in NSDL | 11230883 | 25.65 |
| 14. Physical : | 87429 | 0.20 |
| 15. Total no. of shares : (12+13+14) | 43787944 | 100.00 |
16. Reasons for difference if any, between (10 & 11), (10 & 15), (11 & 15) : **N.A**
17. Certifying the details of changes in share capital during the quarter under consideration as per Table below :

Particulars	No. of shares	Applied/ Not Applied for listing	Listed on Stock Exchange (Specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In - prin. Approval pending for SE (specify names)
1	32840958	Applied	BSE	Yes	Yes	No

Note: The Company has issued and allotted 32840958 equity shares by way of bonus issue during the quarter and received Trading Approval from BSE Ltd. on 28th June, 2024.



Ravi Kapoor & Associates

4th Floor,
"Shaival Plaza",
Gujarat College Road,
Ellisbridge, Ahmedabad-380 006.
© 26420336/7/9 (R) 26568212
(M) 98250 63147
E-mail : ravi@ravics.com www.ravics.com

Company Secretaries

Trade Mark Agent

Insolvency Resolution Professional

18. Register of members is updated : (Yes/ No) :

19. Reference of previous quarter with regards to excess dematerialised shares, if any

20. Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason, why?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total no. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days	Nil		Nil N.A.
Pending for more than 21 days	Nil		Nil N.A.

22. Name, Telephone & Fax No. of the compliance officer of the Company

Ms. Arpita Kabra
Company Secretary & Compliance Officer
Tel : 079 - 48000430

23. Name, Address, Tel. & Fax No., Regn. No. of the auditor

Mr. Ravi Kapoor
Ravi Kapoor & Associates
4th Floor, Shaival Plaza
Ellisbridge,
Ahmedabad - 380 006
Tel : 079 -26420336
COP No.2407

24. Appointment of common agency for share registry work

Purva Shareregistry (India) Pvt. Ltd.
9 Shiv Shakti Industrial Estate,
J R Boricha Marg. OPP.
Lodha Excelus, Lower Parel
(East), Mumbai - 400 011

Date : 17th July, 2024

Place : Ahmedabad

For, RAVI KAPOOR & ASSOCIATES




RAVI KAPOOR
COP - 2407, FCS - 2587
UDIN: F002587F000757539